patients with PD, or are based on relatively small cross-sectional samples of patients. In addition, most studies rely on patient report of health care use and are often conducted over a short follow-up period, which does not permit calculation of annual changes with disease progression. [10] [11] [12] [13] Long-term follow-up data are lacking, and a combined analysis of primary care and hospital records has not been previously attempted in PD. Long-term data on real-life health care resource utilization and cost of illness are needed to better understand and plan the provision of health care for advancing disease and allow for accurate cost-effectiveness analyses and health care decisionmaking.
The aim of this study was to undertake an assessment of the levels of health care utilization and associated costs in the 10 years after diagnosis in a large sample of PD patients in the United Kingdom.
Methods

Study Design
This study employed a retrospective cohort design using the linked UK databases for primary care and hospital care provision: the Hospital Episode Statistics (HES) database and the UK Clinical Practice Research Datalink (CPRD). Costs were estimated using a health system perspective and included direct medical resource use only. Other costs, such as out-of-pocket expenditures by patients, privately insured spending, and costs of informal and formal caregiving, were not captured. Approval for this study was granted by the Independent Scientific Advisory Committee for Medicines and Healthcare Products Regulatory Agency on May 15, 2015 (ISAC Protocol 14-234Mn).
The study period was April 1, 1993 , to March 31, 2013 . To ensure that patients were newly diagnosed, we excluded patients whose records did not contain a period of at least 12 months prior to the index date (diagnosis of PD or first antiparkinsonian medication prescription). A minimum of 12 months of follow-up data was also required to calculate costs following index diagnosis. We therefore obtained linked HES-CPRD data from April 1, 1992, through March 31, 2014.
Setting and Data Sources
CPRD included detailed primary care medical records for about 5.5 million registered patients from approximately 590 general practices covering 8% of the UK population. The patient population captured in the database has been shown to be representative of the demographic breakdown of the UK population, and the quality and completeness of the data have been well documented for the CPRD's precursor (incorporated into CPRD), the General Practice Research Database (GPRD). [14] [15] [16] [17] [18] [19] Linkage to HES was possible for patients registered with practices in England that use the Vision software system for electronic medical records and have opted into the data linkage scheme. This amounts to approximately half the patients in the CPRD primary care database. Hospital data on the length, type, reasons, and current diagnoses for all National Health Service (NHS) inpatient hospital admissions and accident and emergency (A&E) visits for those who were admitted to the hospital or who were referred to A&E from a general practice (GP), excluding self-referrals to A&E who were not admitted to the hospital, and outpatient clinic attendances (from 2003 onward) were captured regardless of private versus government payer or geographic residency of the patient. 20 GPRD data have been used to answer a wide range of health care quality and resource utilization questions, including several studies of PD. [12] [13] [14] [15] [16] To date, no studies using the linked CPRD-HES database have explored Parkinson's disease. Our study population consisted of patients who had data in the CPRD-HES linked data sets and who met all study criteria (described below).
Selection of Cases
We included all patients aged 30 years and older who were newly diagnosed with PD during the study period. Following previous publications, 21-26 diagnosis of PD was identified using Read codes for PD (see Appendix) in the CPRD-GOLD database or International Classification of Disease (ICD)-10 code "G20.X (Parkinson's disease)" in the HES database and at least 2 prescriptions of antiparkinsonian medication. Prior research has used medical records data to validate that this method correctly identifies 90% of cases. 27 Patients with diagnosis codes for secondary parkinsonism or Parkinson-plus syndromes at any point in their health record and patients with evidence of exposure to agents known to produce parkinsonian syndromes were excluded. 28 A complete list of diagnosis and medication codes used are included in the Appendix.
Selection of Controls
Controls were drawn from the population of adults 30 years old who did not have diagnosis codes indicating primary or secondary parkinsonism at any time during the study period and who had never received prescriptions for drugs to treat PD or drugs known to produce parkinsonism syndromes. In line with the minimum data requirement for cases of 1 year prediagnosis and 1 year postdiagnosis, potential controls were required to have at least 2 years of eligibility during the study period. Initially, 4 potential
control subjects were matched to each case based on sex, birth year (65 years), and general practice where the patient was registered.
To account for possible differences in comorbidities between cases and controls, we used propensity score matching without replacement from among the full set of initially selected potential control subjects. 29, 30 The propensity score was based on logistic regression modeling the probability of having a PD diagnosis as a function of age, sex, and baseline comorbidity (using all comorbid conditions in the Charlson Comorbidity Index with the exception of dementia, as this is a possible clinical feature of PD). Controls were selected using the greedy matching algorithm based on a 5 through > 1 digit match, with cases and controls first matched on the fifth digit of the propensity score and, if no matches are found, on the fourth, third, second, and first digits. 29 Controls were matched with cases after being assigned a pseudo-diagnosis date, ensuring comparability at the index date. However, they were not matched on length of follow-up.
Assessment of Health Care Utilization and Costs
Health care utilization was categorized by setting/ category of service and calculated for 12-month periods from index date for each category: antiparkinsonian medications (number of prescriptions, categorized by product, strength, and formulation) and other medications (number of prescriptions, categorized by 6-digit British National Formulary code), number of primary care episodes, number of outpatient episodes, number of inpatient episodes, and A&E visits. Results are provided for years 1 to 10 from diagnosis.
We used a matched control cost-of-illness (COI) approach [31] [32] [33] to estimate total health care costs and assigned unit costs following standard practice for COI and cost-effectiveness research (detailed in the online Appendix to this article). [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] Consistent with other studies of resource utilization, 44 we estimated total annual costs per patient for each available year of follow-up. To account for inflation and variations in pricing over time, 2013 unit costs were applied to all years. [45] [46] [47] [48] [49] Total costs incorporate direct (eg, medical staff), indirect (eg, administration and security staff), and overhead (eg, facilities) costs. In the summary, costs were converted to 2013 US dollars for comparability with international studies using the UK pound to US dollar 2013 yearly-average exchange rate published by the US Internal Revenue Service (1 UK pound 5 1.5038 US dollars). More details on the methods used to estimate costs for each category of service (eg, inpatient care, primary care) are included with the Appendix.
Data Analysis
Costs (C) attributable to PD were estimated by comparing PD patient total medical costs with those of the matched control cohort as follows:
This approach of using total medical costs among PD patients (as opposed to the costs of PD only) avoids inaccuracies and the practical challenges of assigning each service/procedure to a PD diagnosis. Another benefit of this approach is that it incorporates costs of Parkinson'srelated comorbidities and events (eg, falls related to PD) that might not be assigned a PD diagnosis code but are nonetheless attributable to PD directly (proximate cause) or indirectly (ultimate or distal cause).
Subgroup analyses were undertaken to compare costs for patients with early versus advanced disease. Although there was no definitive consensus in prior research on indicators of PD progression, we used a set of indicators of advanced PD similar to those that have been used in prior research relying on medical records data, 50 which also correspond to the indicators of advanced PD in postmortem studies. 51 We considered a patient to have moved into a more advanced stage of PD if he or she (1) had evidence of the development of motor complications, (2) had received an additional indicative Read or ICD code, or (3) experienced a sentinel event, as follows:
1. Evidence or likelihood of motor complications (eg, dyskinesia) was defined to include a diagnosis code indicating dyskinesia, a prescription for amantadine (rarely used in patients without dyskinesia), or reaching or exceeding a total levodopaequivalent daily dose (LEDD) 52 equal to or greater than 1100 mg-which corresponds to approximate mean baseline levels of LEDD among cases and controls with advanced PD and motor complications in clinical trials of deep brain stimulation for PD 53 -for a minimum of 3 consecutive months in 2 consecutive years (to account for overprescribing during medication changes in 1 year). 2. Additional indicative Read codes that may indicate disease progression including codes for falls, dementia, or psychosis. We included only codes that were recorded more than 2 years following diagnosis of PD to exclude preexisting, non-PDrelated diagnoses or causes. 3. Sentinel events included evidence of first use of a wheelchair, inpatient admission primarily from PD, or a move into a nursing home, each occurring more than 2 years after diagnosis.
All analyses were conducted using SAS software, version 9.3 for Windows. Differences in the matched groups were evaluated using chi-square tests for categorical variables and nonparametric tests (based on 1000 bootstrap replicates) for mean costs. The statistical significance of independent variables in each model was evaluated at the a < 0.05 and < 0.01 level. All analyses were adjusted for the length of follow-up. Subanalyses were also conducted to estimate average annual costs by years of available follow-up for cases and controls.
Results
Baseline Characteristics and Follow-Up
In total, there were 7271 PD patients with linked CPRD-HES data over the study intake period. Of these, matched controls could be found for 7070. The control group was similar in terms of age, sex, and comorbid conditions (Table 1) .
All cases and matched controls had at least 1 year of complete follow-up after the index date. In each subsequent year, more cases than controls were lost to follow-up. At the end of 10 years following diagnosis, 782 PD patients (11.1%) remained in the data versus 3158 of the matched controls (44.7%). On average PD patients had 4.9 6 3.4 years of follow-up data available, compared with 8.7 6 4.3 years for controls. Costs were summarized for cases and controls by years of follow-up (available in the online Appendix).
Health Resource Utilization and Costs: All Patients
Health care utilization
Parkinson's patients used, on average, more health care resources than matched controls in each year following diagnosis. Compared with age-, sex-and comorbidity-matched controls, on average PD patients had nearly twice as many primary care events (68.6 vs 37.1) and inpatient hospital stays (0.7 vs 0.4), double the number of prescriptions for non-PD medications (11.3 vs 5.6), more than twice the rate of A&E visits (0.7 vs 0.3), and almost 3 times as many hospital outpatient visits (Table 2) .
Costs by type of health care utilization Over up to 10 years of follow-up, average cost of health care utilization in PD patients was £5022 6 £4058 per year, compared with £2001 6 £2000 per year in matched controls. Mean costs were significantly higher across all categories of health care utilization, including primary care (by a factor of 1.9), inpatient stays (by a factor of 2.5), A&E attendances (by a factor of 2.7), selected non-PD medications (by a factor of 3.0), and outpatient visits (by a factor of 8.5); see Table 2 .
Overall, primary care episodes accounted for 46.9% of the total costs for PD patients, inpatient stays for 30.2%, non-PD medications for 4.4%, PD medications for 7.7%, and outpatient visits for 9.8%. The largest category, primary care, included 6 types of encounter: clinic (mean 6 SD, 1.7 6 3.7 encounters/ year), telephone (mean 6 SD, 1.7 6 3.9), nonstandard time or location (including out-of-hours and night visits, home/residence visits, and emergencies; mean 6 SD, 2.1 6 4.0), surgery (mean 6 SD, 12.5 6 11.8), administrative (mean 6 SD, 29.0 6 27.7), and other (which included encounters such as "medicine management," "repeat issue," and "third-party consultation"; mean 6 SD, 21.6 6 16.7).
For comparability with prior studies that used patient-reported survey data, [10] [11] [12] [13] we conducted a sensitivity analysis of the impact on total cost of including only direct patient contacts and prescriptions (ie, excluding administrative events and other encounters from the primary care cost estimates). In that case, average total cost of health care utilization in PD patients was £3382 6 £3613 per year, compared with £1192 6 £1524) per year in matched controls. In this case, primary care constitutes 21.1% of total direct health expenditures on PD patients.
Time trends
Average costs were £4050 6 £4326 among PD patients in the first year postdiagnosis and £1580 6 £2555 among controls in the same period, reflecting higher costs among PD patients for all types of care, including primary care, hospitalizations, and prescription drugs. The mean annual cost difference between PD patients and controls was £2471 (P < 0.001) in the first year postdiagnosis, rising to £4004 (P < 0.001) in year 10 ( Fig. 1) . 
C O S T S O F T R E A T I N G P D I N U K
Health Resource Utilization and Costs: Patients With Advanced Disease
Of the 7060 patients, 3958 (56.1%) developed advanced disease at any point during the 10-year follow-up period. The percentage of patients with new indicators of advanced disease increased from 2% 1 year postindex PD diagnosis date to 49% among those with 10 years of follow-up data. Utilization among patients who developed advanced disease was significantly higher annually for inpatient stays, accident and emergency visits, primary care, and non-PD medications, but did not differ for outpatient hospital care or anti-PD medications. On average, during the 10 years of follow-up, patients with advanced PD had annual costs of £5491 6 £3602 compared with £4422 6 £4498 among those without advanced disease (Table 3 ). All expenditure categories were significantly higher among advanced PD patients with the exceptions of outpatient hospital encounters and non-PD medications.
Health Resource Utilization and Costs: Patients With Dementia
Dementia was twice as likely to be recorded among PD patients than control subjects (28.3% vs 14.1%; P < 0.001). During the 10 years of follow-up, PD patients with dementia recorded at any point during follow-up had higher mean costs than those without dementia (£5649 vs £4773; P < 0.001), with the additional costs from dementia at any point during followup being higher among PD versus controls (£876 vs £560; P 5 0.022); see Figure 2 .
Discussion
This is the first study that reports linked primary and secondary care data in the United Kingdom to evaluate short-and long-term costs of treating patients with Parkinson's disease over time. We took a net cost approach to consider all direct medical costs that may be either immediately attributable to PD (proximate cause) or related to a PD diagnosis (ultimate cause). Mean costs attributable to PD rose steadily from £2471 (US$3716) per patient higher in the first year following diagnosis up to £4004 (US$6021) per patient in year 10.
Direct comparison to prior studies is difficult because of different methodologies, such as estimating health care utilization using patient or physician survey data, and differences in reporting, such as total costs. [10] [11] [12] [13] In addition, most studies did not distinguish between patients with early or more advanced disease. The overall costs of health care we attributed to PD alone of £3021 ($4543) were slightly lower than those in a US study using similar methods (annual average over 5 years, $5362, after inflating to 2013 dollars using the medical care component of the US Consumer Price Index). 50 However, they were higher than the average direct health care costs in patients with PD in a survey-based UK study, with a total health care cost of £3382 excluding administrative costs in this study compared with £2836 in the survey-based study (assuming 3.3% growth per year mirroring general UK inflation in the period between the studies). 12 The overall total annual direct health care cost of £5022 in patients with PD in this study is similar to that 
All differences in utilization and costs between controls and cases are significant at P < 0.01. After excluding non-PD specific medications for comparability with prior research, we found approximately the same proportion of formal care costs attributable to PD for hospitalizations (31.3%) as previously reported in the UK. 12 However, the costs of antiparkinsonian medication in the present study were a relatively small contributor (13.5%) to direct cost, in contrast to other studies that attributed approximately 20%-30% of costs to drugs. 12, 55, 56 We found higher primary and outpatient hospital care costs (54.1% of all costs) than McCrone and colleagues who, using a standard NHS survey instrument to assess health care utilization, attributed only 49.0% of costs to primary care, outpatient hospital, and all other health care encounters combined. 12 This difference may be because of problems with accurate recall in patient surveys and the relatively high rate of administrative and other primary care encounters that we found. Of particular note, accessing patient medical records allowed us to capture a range of administrative encounters in primary care (eg, recording patient data from letters sent to GPs by specialists to whom they have referred the patient for care) that cannot be captured using patient surveys.
This study concentrated on the direct health care costs to the health care system and did not capture social services, lost earnings, or informal care costs. Although these costs are more difficult to estimate accurately, they represent a large proportion of costs attributable to PD, particularly in older patients. 11, 12, 50, 57 In 1 study, in patients < 65 years costs to the NHS represented 65% of the overall costs, whereas in older patients costs to the NHS comprised only 21% and were dwarfed by social services costs and private expenditure. 58 A recent report estimated the cost of lost earnings and out-of-pocket expenditures by patients at £16,582 per year. 59 Therefore, if these informal care costs as well as formal social care are considered together with the direct health care costs calculated here, the overall cost of PD for society is estimated to be on average at least £25,000 per person with PD.
This study has some limitations. First, as with other observational studies, we were unable to fully control for unobservable characteristics that may influence resource utilization and costs. Second, because of the limitations of the data available, our estimates of the costs attributable to PD from HES are likely to be conservative because HES outpatient data were not available prior to 2003 and A&E self-referrals that did not result in inpatient admission were not captured in our data. On the other hand, we may have overestimated costs from primary care, as we used an inclusive approach to calculate primary care costs, comprising consultations and administrative and other costs. Although this has the advantage of including all costs, it is likely to overestimate the costs when several events take place at the same time. However, even when restricting the primary care costs to consultations, the overall annual costs for PD were still £3382 compared with £1192 in controls. Third, we may have overestimated the utilization and costs of antiparkinsonian medications. Prescription data in medical records indicate a physician's intention, but do not directly reveal any information regarding patient compliance with prescribed therapies including whether 
prescriptions were filled. On the other hand, some costly PD medications were not available early in our study period or went out of patent protection during that period, and the inclusion of patients diagnosed prior to the introduction of these therapies or after their patent expiry date may have underestimated mean medication costs that would apply to particular years. Fourth, in each year, more cases than control subjects were lost to follow-up. If this was because of higher mortality, then direct medical costs in PD are curtailed. However, given the increasing disability with longer disease duration, it is likely that more PD patients transferred into skilled nursing or long term care facilities. Although our data do not provide sufficient information to determine the reasons for lost follow-up, costs for these patients are likely to be considerably higher than for matched controls, leading to an underestimation of PD-related costs.
In terms of calculating costs associated with markers of advanced disease, these data should be treated as estimates. We did not have the data necessary to directly characterize disease progression (eg, Unified Parkinson's Disease Rating Scale score, Hoehn & Yahr stage), as these are rarely captured in medical records, and we used proxies to indicate advanced disease. Similarly, the costs of associated dementia are estimates, as they are based on recorded diagnoses of dementia rather than cognitive assessments.
The costs reported here do not exactly reflect costs to the NHS of caring for PD patients because primary care physicians are paid a capitated fee per patient that does not take into account disease burden. Given this, the net costs of PD to the NHS would be the costs of all encounters except primary care, because costs for cases and controls would be identical there. However, it is important to take a health system perspective, rather than simply estimating costs to the NHS that do not fully reflect resource utilization.
This study is unique in using linked primary and secondary care medical records data to evaluate costs of treating patients with Parkinson's disease in the UK. Our use of administrative data permitted an unusually long study period, with some patients followed for more than 10 years. Our estimates are clearly conservative in total because we were not able to include nursing homes, social services, lost productivity, or informal care costs. However, we believe that the choice of using a case-control net cost analysis enabled us to provide more complete and accurate estimates of direct medical costs attributable to PD than have previously been reported for the UK. Our method allowed us to highlight the gap between PD patients and age-, sex-and comorbidity-matched controls without PD and show that this gap rises as PD progresses over time.
This study aimed to advance our understanding of health care resource use and costs of PD, critical for resource allocation decisions in this area. Further research, incorporating data on social services expenditures, nursing home and informal care costs, and reduced earnings, is needed to obtain a more complete picture of how costs increase with disease progression. This would strengthen analyses of the long-term costeffectiveness of existing and future therapies to delay or reverse the onset of debilitating effects of the disease and its treatment and would help to inform the development of clinical guidelines and policy decisions.
